MCAD is a dubious disease in the field of genetic metabolism, clinical performance is complex and often involves multi-systematic stress. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspections, laboratory tests and pathological activation.
The platform can help align national and international authorities with teams to provide accurate diagnostics and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, significant improvements have been made in many previously difficult to treat genetic metabolic disorders. Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to the timely schedule of changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of MCAD associated with carcinoma. The platform serves a team of internationally authoritative experts in the field of genetic metabolism at home and abroad in China's international medical service system, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.